Abstract
Interferon gamma (IFNγ) is a potent inflammatory and immune cytokine. IFNγ signals via the interferon gamma receptor (IFNGR), which is constitutively bound to Janus Kinase (JAK) 1 and JAK2 via its intracellular domain. These two JAK proteins then initiate the inflammatory signaling cascade. The most potent inhibitor of IFNγ signaling is Suppressor of Cytokine Signaling 1 (SOCS1). SOCS1 negatively regulates IFNγ signaling pathway (and other pathways) by directly inhibiting JAKs. Here, we describe a protocol for the recombinant production and purification of the JAK1 kinase domain and its inhibitor SOCS1, for structural and biochemical studies.
References
Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189
Haan C, Kreis S, Margue C, Behrmann I (2006) Jaks and cytokine receptors—an intimate relationship. Biochem Pharm 72:1538–1546
Igarashi K, Garotta G, Ozmen L, Ziemiecki A, Wilks AF, Harpur AG et al (1994) Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem 269:14333–14336
Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B (1994) Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265:106–109
Pollard KM, Cauvi DM, Toomey CB, Morris KV, Kono DH (2013) Interferon-gamma and systemic autoimmunity. Discov Med 16:123–131
Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS et al (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597–608
Ihle JN (1995) Cytokine receptor signalling. Nature 377:591–594
Shuai K, Ziemiecki A, Wilks AF, Harpur AG, Sadowski HB, Gilman MZ et al (1993) Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 366:580–583
Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ et al (2008) Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 14:3716–3721
Wallweber HJ, Tam C, Franke Y, Starovasnik MA, Lupardus PJ (2014) Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2. Nat Struct Mol Biol 21:443–448
Ferrao R, Wallweber HJ, Ho H, Tam C, Franke Y, Quinn J et al (2016) The structural basis for class II cytokine receptor recognition by JAK1. Structure 24(6):897–905
Duhe RJ, Clark EA, Farrar WL (2002) Characterization of the in vitro kinase activity of a partially purified soluble GST/JAK2 fusion protein. Mol Cell Biochem 236:23–35
Kershaw NJ, Murphy JM, Liau NPD, Varghese LN, Laktyushin A, Whitlock EL et al (2013) SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 20:469–476
Babon JJ, Varghese LN, Nicola NA (2014) Inhibition of IL-6 family cytokines by SOCS3. Semin Immunol 26:1–7
Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS et al (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 95:114–119
Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ et al (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917–921
Babon JJ, Sabo JK, Soetopo A, Yao S, Bailey MF, Zhang JG et al (2008) The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J Mol Biol 381:928–940
Babon JJ, Sabo JK, Zhang JG, Nicola NA, Norton RS (2009) The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. J Mol Biol 387:162–174
Kershaw NJ, Laktyushin A, Nicola NA, Babon JJ (2014) Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates. Growth Factors 32:1–10
Kershaw NJ, Murphy JM, Lucet IS, Na N, Babon JJ (2013) Regulation of Janus kinases by SOCS proteins. Biochem Soc Trans 41:1042–1047
Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T et al (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18:1309–1320
Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I et al (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4:339–351
Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN et al (2012) Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36:239–250
Harwood S (2007) Small-scale protein production with the baculovirus expression vector system. Methods Mol Biol 388:211–224
Acknowledgments
This work was supported by the Cancer Council Victoria (Grant-in-aid 1065180) and the National Health and Medical Research Council (NHMRC) Australia (Project grant #112299, Program grant #1113577), an NHMRC IRIISS grant 361646, and a Victorian State Government Operational Infrastructure Scheme grant. J.J.B. is supported by an NHMRC fellowship and NPDL by an Australian Postgraduate Award.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Liau, N.P.D., Babon, J.J. (2018). Expression and Purification of JAK1 and SOCS1 for Structural and Biochemical Studies. In: Jenkins, B. (eds) Inflammation and Cancer. Methods in Molecular Biology, vol 1725. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7568-6_21
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7568-6_21
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7567-9
Online ISBN: 978-1-4939-7568-6
eBook Packages: Springer Protocols